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1. Introduction
Since Dr Kanji Inoue introduced the Inoue balloon catheter in 1984, percutaneous balloon
valvuloplasty (PBMV) has become the treatment of choice for patients with symptomatic mitral
valve stenosis and favorable valve morphology. PBMV is the preferred treatment for mitral
stenosis as it is less invasive and provides longer-lasting results than closed commissurotomy.
1 PMBV is not suited for patients with mitral stenosis due to severe annular calcification or
markedly degenerated valves. PBMV can be performed either an in antegrade fashion through
a transseptal puncture or retrograde from the aorta to the mitral valve. Serial balloon dila‐
tions of the mitral valve using the self-centering Inoue balloon catheter (or alternatively, a
standard valvuloplasty balloon catheter) are performed to physically split the mitral valve
leaflet commissures and subsequently improve leaflet motion and hemodynamics. In success‐
ful cases, percutaneous balloon mitral valvuloplasty typically doubles the mitral valve area and
decreases the mitral valve gradient by half.  Splitting of the commissures is the principle
mechanism that leads to improvement of hemodynamics and patient symptomatology.
The anatomy of the mitral valve is complex, and echocardiographic imaging plays a critical
role in both the diagnosis and guidance of management of patients with mitral stenosis.
Although Doppler hemodynamics and 2D transthoracic echocardiography are a mainstay in
the echocardiographic assessment of mitral stenosis (Figure 1), real-time three-dimensional
echocardiography (RT3DE) is an emerging imaging tool for not only the diagnosis of mitral
stenosis (Figure 2), but also for the guidance of percutaneous balloon mitral valvuloplasty
procedures in the catheterization laboratory.
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RV: right ventricle; LV: left ventricle; RA: right atrium; LA: left atrium
Figure 1. Two dimensional and Doppler echocardiography in mitral stenosis. Traditionally 2D echocardiography has
provided structural information regarding the morphology of the mitral valve in mitral stenosis. In addition chamber
size, and ventricular function is assessed by echocardiography. Doppler methods provide hemodynamic functional in‐
formation regarding the mitral valve in mitral stenosis. Peak and mean mitral valve gradients, pressure half time de‐
rived mitral valve area and systolic pulmonary pressure are usually recorded in these patients.
2. Diagnosis
Diagnosis of mitral valve stenosis commonly involves the use of 2D transthoracic echocar‐
diography (2DE) to assess the severity of mitral disease, including mitral leaflet mobility,
thickening, calcification and sub-valvular stenosis; as well as to exclude any contraindications
to treatment, such us left atrial thrombus or significant mitral regurgitation.
Normal mitral valve area (MVA) is approximately 4-6 cm2. Patients with symptomatic mitral
stenosis typically have a valve area of less than 2.0 cm2 and have severe mitral stenosis if the
valve area is less than 1.0 cm2.[2] (Figure 3) The narrowing of the mitral orifice creates a left
atrioventricular pressure gradient (the hemodynamic hallmark of mitral stenosis), which in a
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normal functioning mitral valve is near zero. In the setting of hemodynamically significant
mitral stenosis, patients can present with a constellation of symptoms that may include
dyspnea, orthopnea, paroxysmal nocturnal dyspnea, lower extremity edema, poor exercise
tolerance and/or palpitations.
3. Modalities used to evaluate the mitral valve
Various echocardiographic techniques can be used to measure mitral valve area, including
pressure half-time (PHT), planimetry, continuity equation and proximal iso-velocity surface
area (PISA). Each method has its own advantages and disadvantages.
Planimetry has shown to be more accurate when measuring MVA post PBMV compared to
PHT, PISA or the continuity equation method.[3],[4] Planimetry involves the direct measure‐
ment of the mitral valve orifice and has correlated well with invasive anatomic measurement.
[1] This method requires a considerable amount of expertise for reliability.
RV: right ventricle; LV: left ventricle; RA: right atrium; LA: left atrium; Ao: Aorta
Figure 2. Comparison of 2D and 3D transthoracic echocardiography in mitral stenosis. The most useful views to evalu‐
ate patients with mitral stenosis include the apical 4 chamber view as well as the parasternal long and short axis views.
This figure illustrates the added value of 3D imaging in better characterizing the mitral valve apparatus. The third di‐
mension increases the anatomic detail of the leaflets, commissures and subvalvular tissue.
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The PHT method is easily performed, but is influenced by other concomitant valvular disease,
such as aortic or mitral regurgitation, or by the dynamic hemodynamics seen post-PBMV.[4],
[6],[7] In contrast, planimetry is not affected by hemodynamic variability, but is difficult
because it requires technically challenging imaging views of the mitral orifice.
The PISA method requires many different imaging planes and variables to accurately calculate
MVA and thus is very laborious. It can be however, used in the presence of mitral regurgitation
dynamic flow changes.[7]
The continuity equation also involves the measurements of many variables, including size of
the left ventricular outflow tract and mitral annulus. It also cannot be used in patients with
atrial fibrillation or significant aortic or mitral regurgitation.
Planimetry has become the most reliable method for calculating mitral valve area and has been
compared to the invasively derived Gorlin’s formula, which by some is considered the gold
standard for mitral valve area calculation.[2] However, real-time 3D echocardiography
(RT3DE) may be a more accurate and feasible method for calculating MVA in patients being
evaluated for PBMV.[6] Planimetry with 2DE relies on good echocardiographic technique and
Figure 3. Normal mitral valve compared to mitral valves with moderate and severe mitral stenosis.The mitral valve ori‐
fice is seen from the left atrial side (LA view-white asterisk) and the left ventricular side (LV View- green asterisk) in a
patient with a normal mitral valve (valve area 4cm2, a patient with moderate mitral stenosis ( valve area of 1.2 cm2),
and in a patient with severe mitral stenosis ( valve area of 0.8 cm2).
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imaging windows in the parasternal short-axis plane to directly measure the mitral valve
orifice. In contrast, RT3DE is not limited to a specific imaging plane and can image the mitral
valve in several different planes, allowing for a recreation of a 3D image for precise tracing of
the mitral valve orifice.(Figure 4) Even though poor imaging windows can affect both 2D and
3D echocardiography, RT3DE has been less affected by poor imaging windows compared to
2D.[8],[9] Real-time 3D echocardiography has been shown to be more accurate and reliable
than 2DE planimetry for assessing MVA, severity of commissural fusion and extent of sub-
valvular disease.[8],[10] Real-time 3D echocardiography has also been shown to provide a
more accurate and reliable MVA measurement in inexperienced echocardiographers using
RT3DE compared to 2D echocardiography and nominally affected by mitral valve morphology
and post-PBMV hemodynamic changes.[6],[8],[10]-[11]
The asterisks represent the mitral valve orifice from each of the 3 orthogonal planes. RV: right ventricle; LV: left ventri‐
cle; RA: right atrium; LA: left atrium
Figure 4. Multiplane reconstruction of the mitral valve apparatus in mitral stenosis. 3D echocardiography can be pre‐
sented in a volume rendition form (panel D) or in a simultaneous multiplane rendition (panels A, B and C). From the
long axis plane (panel A) one can choose the tips of the leaflets to obtain the true minimal mitral valve orifice area, as
depicted in panel B. Panel C represents an orthogonal view at the bi-commissural level, a view that is not obtainable
from 2D echo alone.
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4. Patient selection
Favorable  patients  for  percutaneous balloon mitral  valvuloplasty are  typically  evaluated
through calculation of the echocardiographic Wilkin’s score (Figure 5). It is the most widely
used prognostic score to determine a favorable PBMV outcome. It is derived non-invasively by
echocardiography using four variables, valve leaflet mobility, thickening, calcification and
degree of sub-valvular thickening. The Wilkin’s score assigns a value from 1 to 4 for each
category, with a higher value indicating more extensive disease. A patient is considered a good
candidate for PBMV if they have a total score of ≤ 8 and the absence of severe mitral regurgita‐
tion. An optimal patient is associated with a high level of procedural success and low compli‐
cation rate. Patients with scores > 8 have an increased risk for adverse outcomes and should be
considered for surgical management.[12] However, even in unfavorable candidates percutane‐
ous balloon valvuloplasty is often still the first treatment of choice in experienced centers.
Grade Mobility Thickening Calcification Subvalvular disease
1
Highly mobile with
only leaflet tips
restricted
Leaflets near normal
in thickness
(4-5mm)
A single area of
increased echo
brightness
Minimal thickening just
below the mitral leaflets
2
Leaflet mid portions
and base portions
have normal mobility
Midleaflets normal,
considerable
thickening of
margins (5-8mm)
Scattered areas of
brightness confined
to leaflet margins
Thickening of chordal
structures extending to one
of the chordal length
3
Valve continues to
move forward in
diastole, mainly from
the base
Thickening extending
through the entire
leaflets
(5-8mm)
Brightness extending
into the mid portions
of the leaflets
Thickening extended to
distal third of the chords
4
No or minimal
forward movement
of the leaflets in
diastole
Considerable
thickening of all
leaflet tissue
("/>8-10mm)
Extensive brightness
throughout much of
the leaflet tissue
Extensive thickening and
shortening of all chordal
structures extending down
to the papillary muscle
Adapted from Wilkins et al.[12]
Table 1. Mitral Valve Anatomy Scoring Using the Wilkin’s Score
Iung and Cormier also developed a scoring system to evaluate mitral valve anatomy in a less
complex way. In addition, the Cormier scoring system also factors in chordae length, a feature
not included in the more traditional Wilkins score. Interestingly, however, neither the Wilkins
or Cormier scoring systems address the issue of commissure disease, such as fusion and extent
of calcification. Inadequate leaflet splitting and the development of mitral regurgitation can
be related to severe commissural disease.[14]-[16] Identifying the degree of commissural
disease can help to predict poor patient outcomes. Because of the potential importance of
commissural disease in PBMV outcomes, there is interest in incorporating this variable into a
new, RT3DE-derived mitral stenosis scoring system.[9]
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RV: right ventricle; LV: left ventricle; RA: right atrium; LA: left atrium; Ao: Aorta
Figure 5. Splitability scores obtained in three patients with mitral stenosis. Diastolic frames are depicted to the left
and systolic frames to the right. The upper panels are from a patient with a Splitability score of 4, which would make
him a good balloon valvuloplasty candidate. The middle panels are from a patient with a score of 9 which would make
him a borderline candidate for valvuloplasty. The lower panels are from a poor candidate for balloon valvuloplasty
with a score of 13.
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Echocardiographic Grade Mitral valve anatomy
1 Pliable non-calcified anterior mitral leaflet and mild subvalvular disease (i.e., thin chordae10mm long)
2 Pliable non-calcified anterior mitral leaflet and severe subvalvular disease (i.e., thickenedchordae < 10mm long)
3 Calcification of mitral valve of any extent, as assessed by fluoroscopy, whatever state of thesubvalvular apparatus.
Adapted by Iung B et al.[13]
Table 2. Cormier Score
When compared to 2DE, real-time 3D echocardiography allows for superior visualization of
the mitral valve and sub-valvular anatomy. (Figure 2) Specifically, real-time 3D echocardiog‐
raphy allows for better resolution of mitral leaflet thickening and annular calcification and
enhanced anatomic detail of chordal thickening and separation.[9] Commissural separation,
a key determinate of PBMV success is also better assessed by RT3DE.[10] Finally, leaflet
calcification, including distribution of calcium is better visualized with RT3DE. This is
important because leaflet calcification is a strong predictor of commissural splitting. The
presence of calcification also can help predict adverse outcomes such as embolic stroke or
conduction abnormalities.[9]
1. Persistent left atrial or left atrial appendage thrombus
2. Severe mitral regurgitation
3. Massive or bicommissural calcification
4. Severe concomitant aortic valve or severe tricuspid regurgitation or stenosis
5. Severe concomitant coronary artery disease requiring bypass surgery
Adapted from ACC/AHA 2006 Guidelines for the management of valvular heart disease.[17]
Table 3. Contraindications to percutaneous balloon mitral valvuloplasty
Contraindications to PBMV are listed in Table 3. However, with the advancement of technique
and imaging, even “unfavorable” candidates are often considered for PBMV as first line
treatment in experienced centers. Other patient factors such as age, presence of severe
pulmonary hypertension, atrial arrhythmia, history of prior commissurotomy, smaller valve
area, presence of mitral regurgitation, NYHA class IV and surgical risk help determine those
patients best suited for PBMV.[13],[18],[19]
5. Immediate and late results
The successful splitting of the commissures is the primary determinant of procedural success.
A mitral valve gradient that decreases to 50% pre-PBMV gradient and a mitral valve area that
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roughly increases by 100% or > 1.5cm² without significant mitral regurgitation are hemody‐
namic criteria used to gauge success.[20] Other, often unmeasured variables such as exercise
capacity, pulmonary pressures, left atrial pressure and cardiac output also increase respec‐
tively.
At the time of the procedure), we rely heavily on echo evidence of bicommissural splitting,
which is best seen with RT 3D TEE (Figure 6). The reason for this is that patients undergoing
PMBV are usually under general anesthesia, or heavily sedated, which dramatically impacts
the hemodynamics through the valve. An anatomic endpoint, as opposed to a hemodynamic
endpoint, is what is generally used to assess the efficacy of the PMBV.
Yellow asterisk: lateral commissure; red asterisk: medial commissure.
Figure 6. Panels A and D depict the mitral valve orifice as seen from the LV. Note the commissural fusion and the small
mitral orifice in the pre procedure image (Panel A). In panel D, were the commissures are now split and the arealof the
mitral orifice has increased. Panels B and E illustrate the 2D TEE views of the mitral valve pre and post procedure. Note
the increased leaflet distance post procedure. Panels C and F illustrate the transmitral Doppler gradients pre and post
procedure. The pre-procedure gradients had already diminished under general anesthesia and the post procedure
gradients showed only a mild drop despite good bi-commissural splitting. This is not uncommon to see in the immedi‐
ate post procedure studies and is probably related to decreased left atrial compliance, therefore to gage procedural
success; we rely mostly on the 3D visualization of the mitral orifice size and commissural splitting.
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Late re-stenosis is defined as a valve area < 1.5cm² or a > 50% decrease of initial increase in
valve area post- PBMV.[21] Patients with optimal anatomy (Wilkin’s score ≤ 8) have a re-
stenosis rate nearly 15% less for the same time frame of those with non-optimal anatomy.[20]
Favorable long-term results are directly correlated to desirable baseline valve anatomy and
good immediate results of PBMV.[18] Favorable patients with Wilkin’s scores < 8 have less re-
stenosis as those with scores > 8.[20],[22] In addition, several clinical factors have been shown
to influence late PBMV results: NYHA functional class III-IV, age ≥ 70 years atrial fibrillation,
and suboptimal valve morphology after the procedure.[18] Unsuccessful balloon commissur‐
otomy (Figure 7) and incomplete commissural splitting is associated with a higher post-
procedure mitral gradient and smaller post-PBMV valve area.
Yellow asterisk: lateral commissure; red asterisk: medial commissure
AL: anterior leaflet; PL: posterior leaflet
Figure 7. Panels A and D depict the mitral valve orifice as seen from the LA. Note the commissural fusion and the small
mitral orifice in the pre procedure image. In panel D, post procedure, the commissures are not splitted and the area of
the mitral orifice has not increased. Panels B and E illustrate the views of the mitral valve from the left ventricle with
similar findings.. Panels C and F illustrate the transmitral Doppler gradients pre and post procedure showing no signifi‐
cant drop in mean transmitral pressures
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Event-free survival; Table 4, has been shown to be as high as 90% in 5 years or longer after the
procedure.[23]
Study (n) patients Age (yrs) Follow-up (yrs) Event –freeSurvival (%)
Fawzy et al.[24] 520 31 17 31±
Iung et al.[18] 1024 49 10 56±
Palacios et al.[26] 879 55 12 33±
Ben-Farhat et al.[25] 654 34 10 72±
Song et al.[23] 402 44 9 90*
Fawzy [28] 547 31 10 88
Cohen [27] 136 59 5 51*
*Survival without intervention
± Survival without intervention in NYHA I or II
Table 4. Event Free Survival
6. Procedural complications
Rates of success of PBMV can exceed 95% in experienced centers to less than 60% in patients
with unfavorable mitral valve anatomy.[20] A direct relationship exists between the experience
of the interventional cardiologist performing the procedure and the incidence of procedural
complications.[29] Most of the complications of the procedure including, mitral regurgitation,
tamponade and a suboptimal improvement in mitral valve gradient are most often related to
unfavorable mitral valve anatomy (represented by elevated Wilkin’s scores).[7],[12] In
contrast, patients with Wilkin’s scores < 8 have a low rate of complications (< 2%), less re-
stenosis and more than a 90% chance of procedure success.[20]
7. Mitral regurgitation
While mild mitral regurgitation is a common outcome following PBMV and is an under‐
standable consequence of commissurotomy, acute severe mitral regurgitation is fortunate‐
ly a rare complication that develops when the balloon commissurotomy produces a leaflet(s)
tear,  damages  the  sub-valvular  compartment  and/or  causes  chordae  rupture.  This  may
require emergent surgical correction.[19],[27] Severe mitral regurgitation is most often seen
in patients  with severe  orifice  narrowing,  severely  diseased leaflets  and significant  sub-
valvular disease.[20]
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The Brockenbrough procedure creates an iatrogenic inter-atrial septal defect, which usually
carries no hemodynamic significance. However, hemo-pericardium can occur with perforation
of adjacent structures by the Brockenbrough needle with an incidence of 2.0 %.[20] Manipu‐
lation of the catheter in the mitral valve position can lead to an unintended perforation of the
left atrium, left atrial appendage, pulmonary veins, ventricular wall or apex, or aortic root.
These complications can be readily avoided using real-time 3D echocardiography, which can
promptly identify a pericardial effusion and help guide catheterization equipment in intra-
cardiac structures.
8. Procedural guidance and assessment of results
Currently, real-time 3D trans-esophageal echocardiography (RT3DTEE) is often used in the
catheterization laboratory to guide the various steps involved in performing a PBMV proce‐
dure,[30] (Figures 8 and 9) as the guide-wires, catheters and devices used during the procedure
may not be readily apparent when using 2D trans-esophageal echocardiography. RT3DTEE,
LA: left atrium; RA: right atrium; SVC: superior vena cava; AV: aortic valve
Figure 8. transeptal puncture is usually the first step in the mitral valve balloon valvuloplasty. Transesophageal echo‐
cardiography now plays a central role for guiding this procedure. Simultaneous biplane imaging is the preferred TEE
guiding mode. Panel A depicts a bicaval view with the Brockenbrough needle tenting (red arrow) the interatrial sep‐
tum at the level of the fossa ovalis. In panel B the same is illustrated from an orthogonal view at the level of the aortic
valve.
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particularly presented in the x plane format, can effectively visualize the precise location of
the tenting of the septum during septal puncture, thereby increasing the safety of this critical
step.[31] Moreover, real-time 3DTEE can more accurately assess MVA and mitral regurgitation
before and after valvuloplasty, compared to 2DE. RT3DTEE allows for imaging the valve
during balloon dilation, “en face” and possibly avoiding leaflet damage by stepwise balloon
over-dilatation by visualizing commissural splitting and leaflet tears immediately after balloon
dilation.[31] 3D TEE is also useful to help determine whether the balloon is free of the chordal
stuctures prior to inflation. RT3DTEE can accurately determine when optimal MVA balloon
dilatation has been achieved and the procedure can be successfully completed.
Figure 9. Three D TEE guidance is now commonly used to assist with all the phases of mitral balloon valvuloplasty. In
panels A, B and C septal puncture is accomplished and the catheter is advanced through the inter-atrial septum (S)
from the right atrium (RA) to the left atrium (LA). In panels D, E and F the balloon is guided to the mitral orifice and
finally through the mitral valve into the left ventricle. In panels G and H the balloon is aligned to the long axis of the
left ventricle (LV) and in panel I the balloon is inflated.
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9. Conclusion
Percutaneous balloon mitral valvuloplasty has become the first line of treatment in individuals
with symptomatic rheumatic mitral stenosis.
Echocardiographic imaging plays a pivotal role in both the diagnosis of mitral stenosis as well
as the guidance of catheter-based procedures (e.g., PBMV) used in treatment. With the
advancement of ultrasound imaging real-time 3D echocardiography supplements current 2D
technology and offers an advantage over conventional echocardiography for the evaluation
of patients being considered for percutaneous balloon mitral valvuloplasty. With the large
number of factors that play a role in determining patients suitability for PBMV as well the risk
for poor outcomes, further defining patient anatomy with advanced imaging such as real-time
3D echocardiography should improve both short and long-term outcomes.
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